IMBdx
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
IMBdx develops blood-based cancer tests that detect tumour DNA circulating in a patient's bloodstream, a technique called liquid biopsy, allowing cancer to be diagnosed, monitored after surgery, or screened for early without removing tissue from the body.
Its tests serve cancer patients and clinicians across three areas: profiling advanced cancers to guide treatment, detecting early signs of recurrence after surgery, and screening for cancer before symptoms appear. Listed on KOSDAQ, Korea's tech-focused stock exchange, the company combines liquid biopsy with next-generation sequencing, a method that reads millions of genetic fragments simultaneously, to cover the full cancer-care continuum within a single product portfolio.
Summary is AI-generated and may contain errors · figures from DART filings
IMBdx in five facts
What does IMBdx do?
IMBdx develops blood-based cancer tests that detect tumour DNA circulating in a patient's bloodstream, a technique called liquid biopsy, allowing cancer to be diagnosed, monitored after surgery, or screened for early without removing tissue from the body.
Where is IMBdx listed and in which sector?
IMBdx (Korean name: 아이엠비디엑스) trades under KRX code 461030 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is IMBdx?
Its market capitalisation was US$27.6M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were IMBdx's latest annual revenue and operating profit?
For fiscal year 2025, IMBdx reported revenue of US$4M, an operating loss of US$6.5M and a net loss of US$6M, per its annual report on DART (data retrieved from DART on 2026-06-04). Revenue was up 56.4% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-06-04
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.